Cargando…

Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report

Here, we discuss the safety and management of adverse events associated with pembrolizumab plus axitinib combination therapy for metastatic renal cell carcinoma in patients on hemodialysis. A 76-year-old man was diagnosed with cT3aN0M0 renal cell carcinoma due to gross hematuria. Stereoscopic radiot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katsumata, Yuki, Kawasaki, Yoshihide, Tanaka, Kayu, Nakayama, Daisuke, Katayama, Hiromichi, Shimada, Shuichi, Satake, Yohei, Sato, Takuma, Kawamorita, Naoki, Yamashita, Shinichi, Sato, Testuya, Shoji, Kosuke, Mitsuzuka, Koji, Ito, Akihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613611/ https://www.ncbi.nlm.nih.gov/pubmed/34899246 http://dx.doi.org/10.1159/000519855

Ejemplares similares

Deliberation on Deferred Cytoreductive Nephrectomy and Postoperative Treatment for Advanced Renal Cell Carcinoma: A Case Report
por: Nakagawa, Takuya, et al.
Publicado: (2022)

Accurate quantification of urinary metabolites for predictive models manifest clinicopathology of renal cell carcinoma
por: Sato, Tomonori, et al.
Publicado: (2020)

Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma
por: Sato, Tomonori, et al.
Publicado: (2020)

Predictive model for recurrence of renal cell carcinoma by comparing pre‐ and postoperative urinary metabolite concentrations
por: Morozumi, Kento, et al.
Publicado: (2021)

BK Virus-Associated Urothelial Carcinoma in a Patient with Peripheral Blood Stem Cell Transplantation for Acute Lymphoblastic Leukemia: A Case Report
por: Koyama, Juntaro, et al.
Publicado: (2021)

Life-threatening Hyperkalemia Associated with Axitinib Treatment in Patients with Recurrent Renal Carcinoma
por: Godo, Shigeo, et al.
Publicado: (2018)

Phosphodiesterase type 5 inhibitor administered immediately after radical prostatectomy temporarily increases the need for incontinence pads, but improves final continence status
por: Kaiho, Yasuhiro, et al.
Publicado: (2016)

A case of testicular cancer with retroperitoneal lymph node metastasis of teratoma with somatic‐type malignancy 18 years after initial treatment
por: Yamashita, Maiko, et al.
Publicado: (2023)

Axitinib/pembrolizumab: Tumour-lysis-syndrome: case report
Publicado: (2020)

Clinical predictors of the estimated glomerular filtration rate 1 year after radical nephrectomy in Japanese patients
por: Shimada, Shuichi, et al.
Publicado: (2017)

Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation
por: Vlachostergios, Panagiotis J.
Publicado: (2020)

Low-energy shock wave therapy ameliorates ischemic-induced overactive bladder in a rat model
por: Kimura, Shingo, et al.
Publicado: (2022)

Author Correction: Low-energy shock wave therapy ameliorates ischemic-induced overactive bladder in a rat model
por: Kimura, Shingo, et al.
Publicado: (2023)

Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)
por: Gurruchaga Sotés, Ibon, et al.
Publicado: (2021)

Pembrolizumab‐axitinib‐induced tumor lysis syndrome in a patient with metastatic renal cancer
por: Shah, Manan, et al.
Publicado: (2020)

Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long‐term treatment‐free survival with pembrolizumab and axitinib in the KEYNOTE‐426 phase III trial of pembrolizumab and axitinib versus sunitinib
por: Nishimoto, Koshiro, et al.
Publicado: (2022)

Autoimmune Myasthenia, Primary Adrenal Insufficiency, and Progressive Hypothyroidism Due to Pembrolizumab and Axitinib Combination Regimen
por: Figueroa-Perez, Nikole, et al.
Publicado: (2021)

Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients
por: Boutros, Andrea, et al.
Publicado: (2022)

Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
por: Chau, Vincent, et al.
Publicado: (2020)

Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)
por: Stellato, Marco, et al.
Publicado: (2023)

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma
por: Zarrabi, Kevin K, et al.
Publicado: (2022)

Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma
por: Atkins, Michael B, et al.
Publicado: (2015)

Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases
por: Tamada, Shinji, et al.
Publicado: (2022)

Pathological Complete Response of Metastatic Clear Cell Renal Carcinoma with Pembrolizumab and Axitinib: A Case Report and Review of Literature
por: Beirat, Amir F., et al.
Publicado: (2023)

Pembrolizumab combined with axitinib in the treatment of skin metastasis of renal clear cell carcinoma to nasal ala: A case report
por: Dong, Shuai, et al.
Publicado: (2023)

Epithelioid Angiomyolipoma with Tumor Thrombus into Inferior Vena Cava Presurgically Treated with Combination Therapy of Pembrolizumab and Axitinib: A Case Report
por: Kawasoe, Chihiro, et al.
Publicado: (2023)

Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands
por: Xander, Nicolas S. H., et al.
Publicado: (2023)

Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
por: Numakura, Kazuyuki, et al.
Publicado: (2021)

Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
por: Watson, Tina R., et al.
Publicado: (2020)

Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States
por: Zakharia, Yousef, et al.
Publicado: (2022)

High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma
por: Sang, Yun Beom, et al.
Publicado: (2022)

Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report
por: Murata, Masaki, et al.
Publicado: (2019)

Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report
por: Olsen, T. Anders, et al.
Publicado: (2021)

Immune‐related dermatitis during combined treatment with pembrolizumab and axitinib in a patient with metastatic renal cell\x92carcinoma with stasis dermatitis
por: Imai, Shunsuke, et al.
Publicado: (2021)

A case of hyperammonemia occurring during treatment of metastatic renal cell carcinoma with axitinib
por: Kimura, Shoichi, et al.
Publicado: (2023)

Selenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity
por: Fu, Ying, et al.
Publicado: (2022)

Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma
por: Osawa, Takahiro, et al.
Publicado: (2020)

Axitinib in Metastatic Renal Cell Carcinoma
por: Mittal, Kriti, et al.
Publicado: (2012)

Axitinib Induces and Aggravates Hypertension Regardless of Prior Treatment With Tyrosine Kinase Inhibitors
por: Kadowaki, Hiroshi, et al.
Publicado: (2021)

The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study
por: Song, Meng‐Jia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l0j50baler49j6piiod41dl284